Versant Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Versant Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,602	Closed	-$38.2K	–	2407
2024 Q3	$38.2K	Buy	4,602 +4,380	+1,973%	+$37.9K	0.01%	552
2024 Q2	$1.59K	Hold	222	–	–	﹤0.01%	1564
2024 Q1	$1.93K	Buy	222 +153	+222%	+$1.03K	﹤0.01%	1366
2023 Q4	$452	Hold	69	–	–	﹤0.01%	1705
2023 Q3	$690	Sell	69 -17	-20%	-$187	﹤0.01%	1633
2023 Q2	$1.07K	Buy	86 +17	+25%	+$229	﹤0.01%	1579
2023 Q1	$957	Sell	69 -25	-27%	-$359	﹤0.01%	1453
2022 Q4	$1.34K	Buy	+94	New	+$1.48K	﹤0.01%	1240
2022 Q3	–	Sell	-9	Closed	–	–	1562
2022 Q2	$0	Sell	9 -7	-44%	-$222	﹤0.01%	1567
2022 Q1	$1K	Buy	+16	New	+$536	﹤0.01%	1323

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Versant Capital Management's MRVI Position: Q4 2024 in Review

Versant Capital Management sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 4,602 shares — an estimated $38.2K sold.

Versant Capital Management first reported a position in MRVI in Q1 2022 and held it in 10 quarters. The position peaked at $38.2K in Q3 2024. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

Versant Capital Management reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
Versant Capital Management sold 4,602 Maravai LifeSciences shares in Q4 2024, an estimated $38.2K.
Versant Capital Management first reported a position in Maravai LifeSciences in Q1 2022 and held it in 10 quarters.
Versant Capital Management's Maravai LifeSciences position peaked at $38.2K in Q3 2024.
185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Versant Capital Management's 13F filing for Q4 2024, filed 3 Jan 2025.